A na

tura

l sol

utio

n to!

deliv

er m

edic

ines

to!

the

brai

n!

OCT

OBE

R!

2014

!bi

Oas

is.ca

!

OTC

QX:

BIO

AF!

TSX.

V: B

TI!

OTCQ

X: B

IOAF

TS

X.V:

BTI

Forw

ard

Look

ing S

tate

men

ts

Certa

in s

tate

men

ts in

this

pres

s re

leas

e co

ntai

n fo

rwar

d-lo

okin

g st

atem

ents

with

in th

e m

eani

ng o

f the

Priv

ate

Secu

ritie

s Li

tigat

ion

Refo

rm A

ct o

f 19

95 o

r fo

rwar

d-lo

okin

g in

form

atio

n un

der

appl

icab

le C

anad

ian

secu

ritie

s le

gisla

tion

that

may

not

be

base

d on

hi

stor

ical

fact

, inc

ludi

ng w

ithou

t lim

itatio

n st

atem

ents

con

tain

ing

the

wor

ds “

belie

ve”,

“may

”, “p

lan”

, “w

ill”, “

estim

ate”

, “co

ntin

ue”,

“ant

icip

ate”

, “in

tend

”, “e

xpec

t” a

nd s

imila

r exp

ress

ions

. Suc

h fo

rwar

d-lo

okin

g st

atem

ents

or i

nfor

mat

ion

invo

lve k

now

n an

d un

know

n ris

ks, u

ncer

tain

ties

and

othe

r fac

tors

that

may

cau

se o

ur a

ctua

l res

ults

, eve

nts

or d

evel

opm

ents

, or i

ndus

try re

sults

, to

be m

ater

ially

diffe

rent

from

any

futu

re re

sults

, eve

nts

or d

evel

opm

ents

exp

ress

or i

mpl

ied

by s

uch

forw

ard-

look

ing

stat

emen

ts o

r inf

orm

atio

n.

Such

fact

ors

incl

ude,

am

ong

othe

rs, o

ur s

tage

of d

evel

opm

ent,

lack

of a

ny p

rodu

ct re

venu

es, a

dditi

onal

cap

ital r

equi

rem

ents

, risk

as

soci

ated

with

the

com

plet

ion

of c

linic

al tr

ials

and

obta

inin

g re

gula

tory

app

rova

l to

mar

ket o

ur p

rodu

cts,

the

abilit

y to

pro

tect

our

in

telle

ctua

l pro

perty

, dep

ende

nce

on c

olla

bora

tive

partn

ers

and

the

pros

pect

s fo

r neg

otia

ting

addi

tiona

l cor

pora

te c

olla

bora

tions

or

licen

sing

arra

ngem

ents

and

thei

r tim

ing.

Spe

cific

ally,

cer

tain

risk

s an

d un

certa

intie

s th

at c

ould

cau

se s

uch

actu

al e

vent

s or

resu

lts

expr

esse

d or

impl

ied

by s

uch

forw

ard-

look

ing

stat

emen

ts a

nd in

form

atio

n to

diff

er m

ater

ially

fro

m a

ny f

utur

e ev

ents

or

resu

lts

expr

esse

d or

impl

ied

by s

uch

stat

emen

ts a

nd in

form

atio

n in

clud

e, b

ut a

re n

ot li

mite

d to

, the

risk

s an

d un

certa

intie

s th

at: p

rodu

cts

that

we

deve

lop

may

not

suc

ceed

in p

recl

inic

al o

r clin

ical

tria

ls, o

r fut

ure

prod

ucts

in o

ur ta

rget

ed c

orpo

rate

obj

ectiv

es; o

ur fu

ture

op

erat

ing

resu

lts a

re u

ncer

tain

and

like

ly to

fluc

tuat

e; w

e m

ay n

ot b

e ab

le to

raise

add

ition

al c

apita

l; w

e m

ay n

ot b

e su

cces

sful

in

esta

blish

ing

addi

tiona

l cor

pora

te c

olla

bora

tions

or l

icen

sing

arra

ngem

ents

; we

may

not

be

able

to e

stab

lish

mar

ketin

g an

d th

e co

sts

of la

unch

ing

our

prod

ucts

may

be

grea

ter

than

ant

icip

ated

; w

e ha

ve n

o ex

perie

nce

in c

omm

erci

al m

anuf

actu

ring;

we

may

fac

e un

know

n ris

ks r

elat

ed t

o in

telle

ctua

l pr

oper

ty m

atte

rs;

we

face

inc

reas

ed c

ompe

titio

n fro

m p

harm

aceu

tical

and

bio

tech

nolo

gy

com

pani

es;

and

othe

r fa

ctor

s as

des

crib

ed i

n de

tail

in o

ur fi

lings

with

the

Can

adia

n se

curit

ies

regu

lato

ry a

utho

ritie

s at

w

ww.

seda

r.com

.

2"

Give

n th

ese

risks

and

unc

erta

intie

s, y

ou a

re c

autio

ned

not t

o pl

ace

undu

e re

lianc

e on

suc

h fo

rwar

d-lo

okin

g st

atem

ents

and

info

rmat

ion,

whi

ch a

re q

ualifi

ed in

the

ir en

tiret

y by

thi

s ca

utio

nary

sta

tem

ent.

All f

orw

ard-

look

ing

stat

emen

ts a

nd in

form

atio

n m

ade

here

in a

re b

ased

on

our c

urre

nt e

xpec

tatio

ns a

nd w

e un

derta

ke n

o ob

ligat

ion

to re

vise

or u

pdat

e su

ch fo

rwar

d- lo

okin

g st

atem

ents

and

info

rmat

ion

to re

flect

sub

sequ

ent e

vent

s or

circ

umst

ance

s, e

xcep

t as

requ

ired

by la

w.

OTCQ

X: B

IOAF

TS

X.V:

BTI

Cent

ral N

ervo

us S

yste

m D

iseas

es

3"

1) (

2012

). Br

ain

Fact

s; A

Prim

er o

n th

e Br

ain

and

Nerv

ous

Syst

em .

Publ

icat

ion,

Soc

iety

for N

euro

scie

nce.

2) (

2007

). Ne

urol

ogic

al d

isord

ers:

Pub

lic h

ealth

cha

lleng

es .

Stud

y, UN

Wor

ld H

ealth

Org

aniza

tion

. 3) b

cc R

esea

rch

. (20

10, S

epte

mbe

r ). T

hera

peut

ic D

rugs

for C

entra

l Ner

vous

Sys

tem

(CNS

) Diso

rder

s: T

echn

olog

ies

and

Glo

bal M

arke

ts,

PHM

068A

.

AFFE

CTS

1 IN

6 P

EOPL

E !

ALL

TREA

TMEN

TS H

INDE

RED

BY T

HE B

LOO

D BR

AIN

BARR

IER

!

12%

of G

lobal

Deat

hs1

12%

Incr

ease

by

2030

1 >1

000

Diffe

rent

Di

seas

es2

>$50

0 Bi

llion

US

Mar

ket2

>$81

.2 B

illion

Drug

M

arke

t3

OTCQ

X: B

IOAF

TS

X.V:

BTI

" Chall

enge

" Th

e Bl

ood

Brain

Bar

rier (

“BBB

”)

Prot

ectiv

e ba

rrier

of t

he c

entra

l ner

vous

sys

tem

(“C

NS”)

prev

entin

g to

xic c

ompo

unds

from

ent

ering

th

e br

ain fr

om th

e cir

culat

ory

syst

em

Prob

lem

BBB

prev

ents

ther

apeu

tics

from

ent

ering

the

brain

in

effic

acio

us le

vels

• ~9

8% o

f sm

all m

olec

ule d

rugs

• 

~100

% o

f larg

e m

olec

ule d

rugs

1

Solut

ion

• bi

Oas

is ha

s di

scov

ered

a n

atur

al oc

curri

ng

phys

iolo

gica

l pro

cess

that

can

tran

spor

t th

erap

eutic

s ac

ross

the

BBB

4"

1) R

oyal

Soc

iety

of C

hem

istry

Tight

ly wo

ven

capil

lary n

etwo

rk o

f en

doth

elial

cells

lining

the

blood

vess

els in

th

e br

ain, w

hich

is re

spon

sible

for

main

taini

ng h

omeo

stas

is

OTCQ

X: B

IOAF

TS

X.V:

BTI

Wha

t we

do…

Drug

Deli

very

Plat

form

Pa

tent

ed fa

mily

of c

arrie

rs, w

hich

deliv

ers

med

icine

s ac

ross

the

BBB

for t

he tr

eatm

ent o

f CN

S di

seas

es

Pote

ntial

trea

tmen

ts fo

r:

Mar

ket L

eadi

ng Te

chno

logy

Th

e Tr

ansc

end

Prog

ram

5"

Brain

Can

cers

M

etab

olic

Dise

ases

Ne

urod

egen

erat

ive

Dise

ases

OTCQ

X: B

IOAF

TS

X.V:

BTI

Brea

kthr

ough

Sol

utio

n

MTf

• Kn

own

as M

elano

trans

ferri

n (M

Tf o

r p97

) • 

Hum

an p

rote

in fo

und

at lo

w c

once

ntra

tions

in th

e bl

ood

• Na

tura

lly d

elive

rs ir

on to

the

brain

• 

Tech

nolo

gy p

aten

ted

by th

e Un

ivers

ity o

f Brit

ish

Colum

bia;

late

r acq

uired

by

biO

asis

6"

The

Tran

scen

d Pr

ogra

m

A na

tura

lly o

ccur

ring

biol

ogica

l pro

cess

that

can

be

expl

oite

d to

deli

ver t

hera

peut

ics a

cros

s th

e BB

B an

d int

o th

e br

ain ti

ssue

to tr

eat m

any

neur

olog

ical d

iseas

es a

nd b

rain

diso

rder

s

MTf

p

• A

new

ly di

scov

ered

pep

tide

foun

d w

ithin

the

full

lengt

h pr

otein

(MTf

), w

hich

offe

rs im

prov

ed b

rain

pene

tratio

n an

d gr

eate

r com

mer

cial p

oten

tial

OTCQ

X: B

IOAF

TS

X.V:

BTI

Adva

ntag

e of

MTf

p

! 

Gre

ater

effic

iency

of B

BB d

elive

ry

! 

Low

er c

ost o

f pro

duct

ion

! 

Impr

oved

qua

lity c

ontro

l ! 

Sim

pler

to lin

k to

ther

apeu

tics

! 

Tran

spor

ts a

var

iety

of c

ompo

unds

w

ith n

o ap

pare

nt s

ize lim

itatio

n ! 

Exte

nds

biO

asis

pate

nt p

ortfo

lio

! 

Phar

mac

eutic

al co

llabo

rato

rs

curre

ntly

licen

sing

MTf

p

7"

BBB"

MTf

p in

Actio

n

MTf

p Th

erap

eutic

OTCQ

X: B

IOAF

TS

X.V:

BTI

Mar

ket O

ppor

tunit

ies

Majo

r Unm

et M

edica

l Nee

d 20

14 D

rug

Mar

ket E

stim

ates

8"

A ca

rrier t

o cr

oss

the

BBB

would

est

ablis

h a

foot

hold

with

in th

ese

majo

r mar

kets

Ce

ntra

l Ner

vous

Sy

stem

Di

sord

ers

!

Stro

ke &

Tr

aum

atic

Brain

Injur

y In

fect

ion

Lyso

som

al !

Stor

age

Dise

ase !

~$20

Billio

n �

USD

~$81

.2 Bi

llion �

USD

~$7.5 Bi

llion �

USD

>$1.9 Bi

llion �

USD

~$33

.7 Bi

llion �

USD

~$13

8 Billio

n �

USD

~$32

.3

Psyc

hiatry

Billio

n �

USD

Ne

urod

egen

erat

ive

Dise

ase"

Clini

cal

need

met

but

im

prov

ed

BBB

pene

tratio

n

could

inc

reas

e

effica

cy

Pain

& M

igra

ine

"

OTCQ

X: B

IOAF

TS

X.V:

BTI

Brain

Can

cer M

arke

t 20

13 D

rug

Sales

for C

ance

rs, w

hich

frequ

ently

m

etas

tasiz

e in

the

brain

2

9"

1) G

loba

lDat

a “B

rain

Tum

or –

Pip

elin

e As

sess

men

t and

Mar

ket F

orec

asts

to 2

017”

rele

ased

Jan

. 17,

201

1.

2) C

ompa

ny R

epor

ted

Data

Herc

eptin

® (t

rast

uzum

ab)

HER2

+ Br

east

Can

cer

~40%

Met

asta

size

Taxo

l® (P

aclit

axel)

Lung

, ova

rian,

etc.

~35%

Met

asta

size

Ritu

xan®

(Ritu

ximab

) Bl

ood

canc

ers:

lymph

oma,

leuke

mia,

etc.

~24%

Met

asta

size

Erbi

tux®

(Cet

uxim

ab)

Lung

canc

er, co

lon ca

ncer,

etc.

~35%

Met

asta

size

$6.6 Bi

llion �

USD

$7.5 Bi

llion �

USD

$1.9 Bi

llion �

USD

$92 M

illion �

USD

Main!

G

loba

l Bra

in Tu

mou

r Th

erap

ies1

~$

1.4 Bi

llion �

USD

OTCQ

X: B

IOAF

TS

X.V:

BTI

Busin

ess

Opp

ortu

nity

10"

Pate

nt C

liff

Estim

ated

~$2

50 b

illion

in lo

st

reve

nue

from

pat

ent

expi

ratio

ns fr

om 2

012-

2015

1

" 1) 

DeRuiter,"J.,"&"Holston,"P."L."(2012,"June"20)."Drug"Patent"ExpiraEons"and"the"“Patent"Cliff”."U.S."Pharm

."2012;37(6)(Generic"suppl):12S20."

2) 

"(2007)."Neurological"disorders:"Public"health"challenges"."Study,"UN"W

orld"Health"OrganizaEon"."

hZp://w

ww.un.org/apps/news/story.asp?newsid=21689&cr=neurological#.U7iNnBa4klI"

3) 

(2012)."Brain"Facts;"A"Primer"on"the"Brain"and"Nervous"System"."PublicaEon,"Society"for"Neuroscience."

Mar

ket G

row

th

CNS

Drug

Mar

ket w

orth

ove

r $8

1.2

billio

n US

D an

d gr

owing

at

12%

CAG

R (2

012-

2030

)3

"

Unm

et M

edica

l Nee

d O

ver 1

000

uniq

ue C

NS d

iseas

es

with

trea

tmen

ts h

inder

ed b

y dr

ug

deliv

ery

acro

ss th

e BB

B2

"

Offe

rs th

e po

tent

ial fo

r pat

ent

term

exte

nsion

s th

roug

h Ne

w Ch

emica

l Ent

ity (“

NCE”

) on

man

y pre

exist

ing d

rugs

Aid

in th

e de

velop

men

t of n

ew

ther

apies

and

revit

alize

dor

man

t ca

ndida

tes

that

are

pro

ven

effica

cious

but

do

not c

ross

Cont

ribut

e CN

S dr

ug m

arke

t by

open

ing u

p an

indu

stry

that

has

be

en s

tagn

ated

by i

neffe

ctive

br

ain d

rug

deliv

ery

OTCQ

X: B

IOAF

TS

X.V:

BTI

Who

we

are…

Boar

d of

Dire

ctor

s

Rob

Hutc

hison

, Cha

ir &

CEO

Form

er: C

EO &

Chie

f Scie

ntist

at e

Char

ge C

orpo

ratio

n

Chris

Fib

iger

, PhD

Fo

rmer

: Hea

d of

Neu

rosc

ience

, Am

gen;

VP

Neur

oscie

nce,

Eli L

ily &

CS

O, B

iova

il Lab

orat

ories

Gre

g G

ubitz

, LLB

Fo

rmer

: VP,

Bio

vail C

orpo

ratio

n &

COO

, MDS

Cap

ital

Terry

Pea

rson

, PhD

Pr

ofes

sor:

Bioc

hem

istry

& M

icrob

iolo

gy, U

VIC

Ron

Erick

son

Curre

nt: C

hair

& CE

O, V

isulan

t Tec

hnol

ogies

M

ichae

l Hut

chiso

n, Q

C, L

LB

Partn

er, S

mith

Hut

chiso

n La

w C

orpo

ratio

n

Team

Judi

Dall

ing, L

LB, C

FO

Seas

oned

pub

lic c

ompa

ny C

FO a

nd c

orpo

rate

law

yer

Wilfr

ed J

effe

ries,

PhD

, Fou

nding

Scie

ntist

O

xfor

d Un

ivers

ity, M

olec

ular I

mm

unol

ogy

Disc

over

ed p

97’s

abilit

y to

cro

ss th

e BB

B Pr

ofes

sor:

Micr

obio

logy

& Im

mun

olog

y, UB

C Re

inhar

d G

abat

huler

, PhD

, Chie

f Scie

ntist

Form

er: V

P Br

ain R

esea

rch,

Bio

mar

in &

CSO

, Ang

ioch

em In

c.

Mei

Mei

Tian

, PhD

, Scie

ntist

UB

C, M

icrob

iolo

gy a

nd Im

mun

olog

y (p

97 e

xper

tise)

La

ura

Ho, M

Sc, S

cient

ist

UBC,

Micr

obio

logy

and

Imm

unol

ogy

Tiffa

ny To

lmie,

Com

mun

icatio

ns

Hono

urs,

Wilfr

id L

aurie

r Univ

ersit

y

OTCQ

X: B

IOAF

TS

X.V:

BTI

Inde

pend

ent

3rd

party

va

lidat

ion

Expa

nd &

pr

otec

t In

telle

ctu

al

Pro

pert

y

Adva

nce

inter

nal

deve

lopm

ent

prog

ram

s

Colla

bora

te

with

repu

tabl

e ph

arm

aceu

tical

com

panie

s

Corp

orat

e St

rate

gy

12"

• Lo

w-c

ost p

rojec

ts

• Po

tent

ial to

ach

ieve

majo

r mile

ston

es:

"

Sho

rt-M

id-L

arge

M

arke

t Pot

entia

l

• M

any

“sho

ts o

n g

oal”

leadi

ng to

com

mer

cial

trans

actio

ns w

ith

num

erou

s pa

rtner

s/lic

ense

es

• O

ver 3

0 pa

tent

s gr

ante

d fo

r BBB

de

liver

y an

d ne

urod

egen

erat

ive

dise

ases

• Na

tiona

l Res

earc

h Co

uncil

• 

BC C

ance

r Res

earc

h Ce

ntre

• 

Texa

s Te

ch U

niver

sity

Healt

h Sc

ience

s Ce

nter

• So

uthe

rn R

esea

rch

Inst

itute

• Un

ivers

ity o

f Alab

ama

OTCQ

X: B

IOAF

TS

X.V:

BTI

Colla

bora

tions

Stra

tegi

c Co

llabo

ratio

ns

• Ab

bVie

• M

edIm

mun

e • 

UCB

Phar

mac

eutic

als

MTf

p

• M

edIm

mun

e ex

ecut

ed L

icens

e Ag

reem

ent

• O

n-go

ing d

iscus

sions

with

col

labor

ator

s fo

r lic

ensin

g ag

reem

ents

• 

Furth

er d

iscus

sions

with

larg

e ph

arm

aceu

tical

com

panie

s on

licen

sing

and

rese

arch

op

portu

nities

13"

OTCQ

X: B

IOAF

TS

X.V:

BTI

MTf

: Rap

id U

ptak

e in

Brain

14"

Com

poun

d Br

ain K

in (m

L-1/

s-1 /

g-1 )

Refe

renc

e

Glu

cose

9.

5 x

10-3

Smith

(200

3)

Mel

anot

rans

ferri

n (M

Tf) !

6.4

x 10

-4 !

Dem

eule

et a

l. (2

002)!

Mor

phin

e 2.

0 x

10-4

Cist

erni

no e

t al.

(200

1)

Apro

tinin

!1.

6 x

10-4

De

meu

le e

t al.

(200

8)

Insu

lin R

ec A

ntib

ody !

1.0

x 10

-4

Pard

ridge

(199

7)

Leu-

Enke

phal

in

6.0

x 10

-5

Zlok

ovic

(19

87)

Mor

phin

e-6-

Glu

curo

nide

2.

4 x

10-5

Tem

sam

ani e

t al.

(200

5)

RAP

!1.

0 x

10-5

Pa

n (2

004)

Beta

Am

yloid

6.

5 x

10-6

Ba

nks

(199

1)

DADL

E 6.

5 x

10-6

Ch

en (2

002)

TNF-α

4.3

x 10

-6

Pan

(200

2)

Tran

spor

t Effi

cien

cy

Mor

e

Less

In Si

tu B

rain

Upta

ke –

Mea

sure

men

t of R

ate

of Tr

ansp

ort

Competitors""

OTCQ

X: B

IOAF

TS

X.V:

BTI

Deve

lopm

ent P

rogr

ams:

"M

Tf +

Ant

i-Aβ

antib

ody

Resu

lts

MTf

+ a

nti-A

β an

tibod

y co

njuga

te in

crea

ses

trans

port

into

brain

tiss

ue b

y ~5-

fold

Qua

ntita

tive

Imag

e An

alys

is b

y La

ser

Scan

ning

Con

foca

l Mic

rosc

opy

15"

Alzh

eimer

’s Di

seas

e

Anti-

Aβ a

ntib

odies

hav

e un

derg

one

clinic

al tri

als fo

r tre

atm

ent o

f Alzh

eimer

’s di

seas

e

Opp

ortu

nity

Using

ant

ibod

ies d

irect

ed a

t Aβ

are

pot

entia

l the

rape

utics

fo

r red

ucing

am

yloid

plaq

ues

in th

e br

ain

Na

tiona

l Res

earc

h Co

unci

l of C

anad

a (N

RC)

Anti-

Aβ

MTf

+ A

nti-A

β

OTCQ

X: B

IOAF

TS

X.V:

BTI

Deve

lopm

ent P

rogr

am:"

MTf

+ α

-L-id

uron

idas

e (“I

DU”)

Lyso

som

al St

orag

e Di

seas

es

Rare

inhe

rited

met

abol

ic di

seas

es c

ause

d by

an

enzy

me

defic

iency

prim

arily

affe

cting

chil

dren

Hurle

r Syn

drom

e (M

PS I)

Prob

lem

• M

PS I

is ca

used

by

an ID

U de

ficien

cy

• Cu

rrent

ly CN

S ef

fect

s un

treat

able

Resu

lts

• M

Tf +

IDU

(lyso

som

al en

zym

e) c

onjug

ate

incre

ased

IDU

brain

enz

yme

activ

ity

~

4-fo

ld

Opp

ortu

nity

• O

ffers

pro

mise

of a

n en

zym

e re

plac

emen

t th

erap

y

16"

0"0.2"

0.4"

0.6"

0.8"1"1.2"

IDU

MTf

- ID

U

Total"IDU"acEvity"

Capi

llarie

s Pa

renc

hym

a

OTCQ

X: B

IOAF

TS

X.V:

BTI

Deve

lopm

ent P

rogr

am:"

MTf

+ id

uron

ate-

2-su

lfata

se (“

IDS”

)

Lyso

som

al St

orag

e Di

seas

es

Rare

inhe

rited

met

abol

ic di

seas

es c

ause

d by

an

enzy

me

defic

iency

prim

arily

affe

cting

chil

dren

Hunt

ers

Synd

rom

e (M

PS II)

Prob

lem

• M

PS II

is ca

used

by

an ID

S de

ficien

cy

• Cu

rrent

ly CN

S ef

fect

s un

treat

able

Resu

lts

• M

Tf +

IDS

(lyso

som

al en

zym

e) c

onjug

ate

incre

ased

IDS

brain

enz

yme

activ

ity

~2

0-fo

ld

Opp

ortu

nity

• O

ffers

pro

mise

of a

n en

zym

e re

plac

emen

t th

erap

y

17"

MTf

+ ID

S En

zym

e en

ters

the

brai

n tis

sue

Nat

ive

Enzy

me

does

not

ent

er th

e br

ain

tissu

e effi

caci

ously

OTCQ

X: B

IOAF

TS

X.V:

BTI

Deve

lopm

ent P

rogr

am: "

MTf

+ D

oxor

ubici

n

• Do

xoru

bicin

is c

urre

ntly

used

as

a ca

ncer

tre

atm

ent (

e.g.

bre

ast,

blad

der,

lung,

ova

ries,

st

omac

h, th

yroi

d, m

ultip

le m

yelo

ma,

leuk

emias

and

Ho

dgkin

's ly

mph

oma)

Prob

lem

• Cu

rrent

ly do

es n

ot p

enet

rate

the

BBB

Resu

lts

• Si

gnific

ant I

NCRE

ASE

in br

ain u

ptak

e w

ith

the

MTf

+ D

oxor

ubici

n co

njuga

te V

S Do

xoru

bicin

alo

ne

Opp

ortu

nity

• W

ould

be

highly

effe

ctive

in tr

eatin

g br

ain

tum

ors

if it c

ould

be

deliv

ered

into

the

brain

18"

0.00"

1.00"

2.00"

3.00"

MTf

+ D

OXO

D

OXO

% IN

JEC

TED

DO

SE

(G T

ISSU

E/G

BO

DY

MAS

S)*1

00%

MTf

Sig

nific

antly

Enh

ance

s D

oxor

ubic

in T

rans

port

into

the

Brai

n

Conju

gate

reta

ins fu

ll ac

tivity

onc

e re

lease

d in

the

brain

OTCQ

X: B

IOAF

TS

X.V:

BTI

MTf

Sig

nifica

ntly

Redu

ces

Doxo

rubi

cin

Upta

ke in

to th

e He

art

Prob

lem

• Do

xoru

bicin

’s m

ost s

erio

us a

dver

se

effe

ct is

life-

thre

aten

ing h

eart

dam

age

Resu

lts

• M

Tf +

Dox

orub

icin

VS D

oxor

ubici

n on

its

own

show

ed a

sig

nifica

nt

DECR

EASE

in u

ptak

e in

the

hear

t

Solut

ion

• Co

uld b

e us

ed to

trea

t bra

in ca

ncer

s an

d de

crea

se h

eart-

upta

ke

side

effe

ct, o

fferin

g inc

reas

ed

usag

e

19"

0.0"

5.0"

10.0"

15.0"

20.0"

% INJECTED DOSE (gram brain tissue/gram body

mass)*100

MTf

+ D

OXO

D

OXO

OTCQ

X: B

IOAF

TS

X.V:

BTI

Deve

lopm

ent P

rogr

am: "

MTf

+ T

rast

uzum

ab (H

erce

ptin®

)

• Tr

astu

zum

ab (H

erce

ptin®

)1 is

a hu

man

ized

mon

oclo

nal a

ntib

ody

used

to tr

eat H

ER2+

bre

ast c

ance

r • 

Annu

al gl

obal

sales

~$6

.6 b

n2

• He

rcep

tin®

incr

ease

s su

rviva

l rat

e bu

t ~40

% p

atien

ts e

vent

ually

de

velo

p br

east

can

cer m

etas

tasis

in

the

brain

3

• Tr

astu

zum

ab (H

erce

ptin®

) doe

s no

t cr

oss

the

BBB

20"

1) H

erce

ptin

® is

a re

gist

ered

trad

emar

k of

Roc

he/G

enen

tech

2) C

ompa

ny R

epor

ted

Data

– 2

013

3) B

ritta

Wei

gelt,

Joh

anne

s L.

Pet

erse

& L

aura

J. v

an't

Veer

. (20

05, A

ugus

t). B

reas

t can

cer

met

asta

sis: m

arke

rs a

nd m

odel

s. N

atur

e Re

view

s Ca

ncer

5 ,

591-

602.

Brai

n C

apill

arie

s

Cel

l Nuc

lei

MTf

+ T

rast

uzum

ab (H

erce

ptin

®)

Conf

ocal

Imag

e Pe

rform

ed b

y iC

aptu

re a

t St

. Pau

l’s H

ospi

tal V

anco

uver

Can

ada

MTf

+ T

rast

uzum

ab (H

erce

ptin

®)

Con

foca

l Im

ages

Tw

o H

ours

Pos

t IV

Adm

inis

trat

ion

OTCQ

X: B

IOAF

TS

X.V:

BTI

Redu

ced

the

num

ber o

f HER

2+ b

reas

t ca

ncer

tum

ors

in th

e br

ain b

y 68

%

MTf

+ T

rast

uzum

ab (H

erce

ptin®

) "In

Vivo

Effic

acy

in Br

east

Can

cer M

odel

21"

0"10"

20"

30"

40"

50"

60"

70"

80"

90"

MTf

""

TZM

" M

Tf-T

ZM "

Salin

e "

""

""

""

Co

ntro

l !

Num

ber o

f Tum

ors

Addi

tiona

l Hig

hligh

ts:

• Th

e tu

mor

s th

at re

main

ed a

fter

treat

men

t had

57%

sm

aller

tu

mou

r vol

ume

• Pe

netra

ted

the

Bloo

d Tu

mou

r Ba

rrier

10

times

bet

ter t

han

Herc

eptin

® a

lone

• 

Incr

ease

d ca

ncer

killi

ng e

ffect

of

Herc

eptin

® w

hen

linke

d w

ith

MTf

OTCQ

X: B

IOAF

TS

X.V:

BTI

Deve

lopm

ent P

rogr

am: "

MTf

p +

siRNA

Small

Inte

rferin

g RN

A (si

RNA)

• Si

lence

s ta

rget

gen

e ex

pres

sion

• 

Targ

eted

gen

e as

socia

ted

with

hum

an d

iseas

es

(i.e

. can

cers

, neu

rode

gene

rativ

e di

seas

es, m

etab

olic

dise

ases

, etc

.)

Prob

lem

• siR

NA d

oes

not c

ross

the

BBB

• G

ene

targ

eting

with

in th

e br

ain is

cur

rent

ly un

achie

vabl

e

Resu

lts

• M

Tf+

siRNA

con

jugat

e de

liver

ed in

to th

e br

ain ti

ssue

• 

Dem

onst

rate

d 40

% to

50%

dec

reas

e in

targ

et g

ene

VS s

iRNA

alo

ne

Opp

ortu

nity

• A

pote

ntial

cor

ners

tone

tech

nolo

gy fo

r the

dev

elopm

ent o

f new

th

erap

eutic

s su

ppre

ssing

dise

ase-

linke

d ge

nes

in th

e br

ain

22"

Natio

nal R

esea

rch

Coun

cil

NO

siR

NA

dete

cted

in B

rain

MTf

+ s

iRN

A de

tect

ed in

Bra

in

OTCQ

X: B

IOAF

TS

X.V:

BTI

Mar

ket P

rofile

"

23"

Data

sou

rce:

S&P

Cap

ital I

Q

Trai

ling

twel

ve m

onth

s as

of M

ay 2

014

Shar

es –

Sep

tem

ber 3

, 201

4

TSX.

V:BT

I; OTC

QX:

BIOA

F Sh

ares

Issu

ed &

Out

stan

ding

43

,805

,507

Fu

lly D

ilute

d

51,6

05,6

09

Opt

ions

5,

855,

625

Dire

ctor

s, o

fficer

s &

empl

oyee

s

War

rant

s

1,94

4,47

7

IP W

arra

nts

Mar

ket C

ap

~$

52.7

m

@ $

1.20

Sha

re P

rice

(Sep

t. 3,

201

4)

Cash

Pos

ition

~$

3m

(May

201

4 Fin

ancia

ls +

Augu

st 2

014

Finan

cing)

Ow

ners

hip

Insid

ers

& Af

filiat

es ~

35%

In

stitu

tiona

l ~10

%

OTCQ

X: B

IOAF

TS

X.V:

BTI 24"

Pipe

line

Brain

Tr

ansp

ort

Brain

Q

uant

ificat

ion

Cellu

lar

Loca

lizat

ion

PD M

odels

Ef

ficac

y

Oncology

Doxo

rubi

cin

[Glio

mas

] Pa

clita

xel

[Tum

ours

] He

rcep

tin

[Bre

ast C

ance

r] Ce

tuxim

ab

[Lun

g Ca

ncer

]

LSD

Hurle

rs S

yndr

ome

MPS

l M

odel

Hunt

ers

Synd

rom

e M

PS II

Mod

el

Sand

hoff

and

Tay-

Sac

s Di

seas

e He

xosa

mini

dase

B M

odel

siRNA

Stro

ke M

odel

ALS

Mod

el

OTCQ

X: B

IOAF

TS

X.V:

BTI

Sum

mar

y

25"

!In

telle

ctua

l Pr

oper

ty

& Co

llabo

ratio

ns

St

rong

pat

ent p

rote

ctio

n Pa

tent

por

tfolio

of >

30 p

aten

ts

Larg

e ph

arm

aceu

tical

colla

bora

tions

Po

sitive

resu

lts;

succ

essf

ul de

mon

stra

tion

Larg

e M

arke

t O

ppor

tunit

ies

Ab

ility

to e

xten

d pa

tent

life

Com

mer

cializ

e ne

w th

erap

eutic

s a

nd/o

r rev

italiz

e do

rman

t ca

ndid

ates

Co

ntrib

ute

to th

e gr

owth

in C

NS d

rug

mar

ket

"

Trea

tmen

t Po

tent

ial

M

etab

olic

dise

ases

Neur

odeg

ener

ative

di

seas

es

Onc

olog

y

"

Aw

arded

TS

X.V

Top

50

® in

2013

Lead

er in

pro

viding

sha

reho

lder v

alue

Mar

ket P

rofile

Goo

d ca

sh p

ositio

n Cl

ean

shar

e st

ruct

ure

Exit

stra

tegy

in p

lace

High

inte

rnal

owne

rship

Man

agem

ent

M

ajor s

ucce

ss in

: Dr

ug c

omm

ercia

lizat

ion

Biot

echn

olog

y &

vent

ure

capi

tal s

tartu

ps

Acad

emia

"

Tr

ansc

end

Prog

ram

“The fi

rst

natu

ral

carr

ier

to e

ffectiv

ely

tr

ansp

ort

thera

peutic

d

rugs

into

the b

rain

.”

Disc

over

y

of M

Tfp

Enha

nced

tech

nolo

gy

Gre

ater

com

mer

cial

pote

ntial

"